Related Experiment Video
Updated: Apr 5, 2026
Establishment of a Clinic-based Biorepository
Published on: May 29, 2017
Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma
Oddveig G Rikardsen1,2, Synnøve N Magnussen3, Gunbjørg Svineng4
1Department of Otorhinolaryngology, University Hospital of North Norway, Tromsø, Norway. oddveig.rikardsen@unn.no.
Background:
Oral squamous cell carcinoma (OSCC) is associated with a poor 5-year survival rate. In general, patients diagnosed with small tumors have a fairly good prognosis, but some small tumors have an aggressive behavior leading to early death. There are at present no reliable prognostic biomarkers for oral cancers. Thus, to optimize treatment for the individual patient, there is a need for biomarkers that can predict tumor behavior.
Method:
In the present study the potential prognostic value of plectin was evaluated by a tissue microarray (TMA) based immunohistochemical analysis of primary tumor tissue obtained from a North Norwegian cohort of 115 patients diagnosed with OSCC. The expression of plectin was compared with clinicopathological variables and 5 year survival.
Results:
The statistical analysis revealed that low expression of plectin in the tumor cells predicted a favorable outcome for patients with non-metastatic disease (p = 0.008). Furthermore, the expression of plectin was found to correlate (p = 0.01) with the expression of uPAR, which we have previously found to be a potential prognostic marker for T1N0 tumors.
Conclusions:
Our results indicate that low expression of plectin predicts a favorable outcome for patients with non-metastatic OSCC and the expression level of plectin may therefore be used in the treatment stratification for patients with early stage disease.
